Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496251 | 1.00 | SIGMAR1 (0.48) | SIGMAR1TSHRHSD17B10PTGESKDM4E | |
| SCHEMBL497074 | 0.99 | SIGMAR1 (0.47) | SIGMAR1TSHRHSD17B10PTGESKDM4E | |
| SCHEMBL495853 | 0.82 | ALDH1A1 (0.44) | SIGMAR1HSD17B10KDM4EALDH1A1GRIK1 | |
| SCHEMBL495820 | 0.82 | SIGMAR1 (0.41) | SIGMAR1PTGES | |
| SCHEMBL495525 | 0.82 | ALDH1A1 (0.44) | SIGMAR1HSD17B10KDM4EALDH1A1GRIK1 | |
| SCHEMBL495805 | 0.78 | TSHR (0.54) | TSHRHSD17B10PTGESKDM4EALDH1A1 | |
| SCHEMBL495871 | 0.76 | SIGMAR1 (0.43) | SIGMAR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL495859 | 0.76 | SIGMAR1 (0.43) | SIGMAR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL496067 | 0.74 | TRPV1 (0.51) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL496283 | 0.73 | TRPV1 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | SIGMAR1 923/4885TSHR 4609/4885HSD17B10 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.